Allogeneic CAR T Cells Derived From Younger Donor T Cells Have More Desirable T Cell Phenotype And Better in vitro Functionality Post author:andrewkaretas Post published:May 18, 2022 Post category:PLATFORM/Scientific Publications Continue ReadingAllogeneic CAR T Cells Derived From Younger Donor T Cells Have More Desirable T Cell Phenotype And Better in vitro Functionality
Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma Post author:andrewkaretas Post published:April 20, 2022 Post category:CD70/Scientific Publications Continue ReadingPreclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma
Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma Post author:andrewkaretas Post published:April 18, 2022 Post category:CD70/Scientific Publications Continue ReadingPreclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma
Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors Post author:andrewkaretas Post published:March 18, 2022 Post category:BCMA/Scientific Publications Continue ReadingAllogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors
ALPHA Study: ALLO-501 Produced Deep and Durable Responses in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma, Comparable to Autologous CAR Post author:andrewkaretas Post published:December 21, 2021 Post category:CD19/Scientific Publications Continue ReadingALPHA Study: ALLO-501 Produced Deep and Durable Responses in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma, Comparable to Autologous CAR
UNIVERSAL Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma Post author:andrewkaretas Post published:December 18, 2021 Post category:BCMA/Scientific Publications Continue ReadingUNIVERSAL Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma
ALPHA2 Study: ALLO-501A Allogeneic CAR T in LBCL, Updated Results Continue to Show Encouraging Safety and Efficacy with Consolidation Dosing Post author:andrewkaretas Post published:December 17, 2021 Post category:CD19/Scientific Publications Continue ReadingALPHA2 Study: ALLO-501A Allogeneic CAR T in LBCL, Updated Results Continue to Show Encouraging Safety and Efficacy with Consolidation Dosing
Safety and PK/PD of ALLO-647, an Anti-CD52 Antibody, With Fludarabine (Flu)/Cyclophosphamide (Cy) for Lymphodepletion in Allogeneic CAR T Cell Therapy Post author:andrewkaretas Post published:June 18, 2021 Post category:ALLO-647/Scientific Publications Continue ReadingSafety and PK/PD of ALLO-647, an Anti-CD52 Antibody, With Fludarabine (Flu)/Cyclophosphamide (Cy) for Lymphodepletion in Allogeneic CAR T Cell Therapy
First-In-Human Data of ALLO-501A, An Allogeneic Chimeric Antigen Receptor (CAR) T Cell Therapy, and ALLO-647 in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): ALPHA2 Study Post author:andrewkaretas Post published:June 1, 2021 Post category:CD19/Scientific Publications Continue ReadingFirst-In-Human Data of ALLO-501A, An Allogeneic Chimeric Antigen Receptor (CAR) T Cell Therapy, and ALLO-647 in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): ALPHA2 Study
PD1 TurboCAR™ T Cells: PD1-Resistant CAR T Cells With Programmable Cytokine Signaling Outputs Post author:andrewkaretas Post published:April 18, 2021 Post category:PLATFORM/Scientific Publications Continue ReadingPD1 TurboCAR™ T Cells: PD1-Resistant CAR T Cells With Programmable Cytokine Signaling Outputs
